Spots Global Cancer Trial Database for hodgkin's disease
Every month we try and update this database with for hodgkin's disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease | NCT00129753 | Hodgkin's Disea... Lymphoma | Alemtuzumab (Ca... | 18 Years - | M.D. Anderson Cancer Center | |
| Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease | NCT00000626 | HIV Infections Hodgkin's Disea... | Vinblastine sul... Dacarbazine Filgrastim Bleomycin sulfa... Doxorubicin hyd... | 12 Years - | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | NCT02639559 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Non-Hodgkin's L... Non-Hodgkin Lym... Hodgkin Disease Hodgkins Diseas... Hodgkin's Disea... Multiple Myelom... Myelodysplastic... Myeloproliferat... | BL-8040 Leukapheresis Hematopoietic c... | 18 Years - 75 Years | Washington University School of Medicine | |
| Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) | NCT00368082 | Lymphoma Hodgkin's Disea... Relapse Lymphoma, Non-H... | TGFbeta resista... | - | Baylor College of Medicine | |
| Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy | NCT01085058 | Hodgkin's Disea... Non-Hodgkin Lym... Multiple Myelom... | lenograstim | 18 Years - 70 Years | WiSP Wissenschaftlicher Service Pharma GmbH | |
| Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease | NCT00165412 | Breast Cancer Hodgkin's Disea... | breast MRI Mammogram | 20 Years - | Dana-Farber Cancer Institute | |
| Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies | NCT00718757 | Non-Hodgkins Ly... Hodgkin's Disea... Acute Lymphobla... | Dexamethasone Irinotecan Vincristine | - 21 Years | St. Jude Children's Research Hospital | |
| Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease | NCT01404936 | Lymphoma | Interferon-2A Adriamycin Bleomycin Velban Dacarbazine | - | M.D. Anderson Cancer Center | |
| Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies | NCT01622556 | Hematologic Mal... | Fludarabine Busulfan Thymoglobulin Total Body Irra... Umbilical Cord ... | 18 Years - 70 Years | University of Virginia | |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | NCT00990587 | Hematologic Mal... Acute Lymphocyt... Chronic Lymphoc... Myelodysplasia Acute Myeloid L... Chronic Myeloge... Hodgkin's Disea... | Ciclopirox Olam... | 18 Years - | University Health Network, Toronto | |
| Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies | NCT00150462 | Waldenstrom's M... Non-Hodgkin's L... Hodgkin's Disea... Multiple Myelom... | Carfilzomib Dexamethasone | 18 Years - | Amgen | |
| Efficacy Study of Outpatient Therapy for Lymphoma | NCT00163761 | Non-Hodgkin's L... Hodgkin's Disea... | gemcitabine, vi... gemcitabine, vi... | 18 Years - | Bayside Health | |
| Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors | NCT00179816 | Ewing's Sarcoma Soft Tissue Sar... Hepatoblastoma Hodgkin's Disea... Germ Cell Tumor | High-Dose Chemo... | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease | NCT01404936 | Lymphoma | Interferon-2A Adriamycin Bleomycin Velban Dacarbazine | - | M.D. Anderson Cancer Center | |
| AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease | NCT00396201 | Hodgkin's Disea... | G-CSF Plus Pler... | 18 Years - 70 Years | Sanofi | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF | NCT00952237 | Non-Hodgkin's L... Hodgkin's Disea... Multiple Myelom... Other Plasma Ce... Leukemia | GM-CSF IL-2 | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers | NCT00051311 | Hematologic Neo... | Stem cell trans... Fludarabine Cyclophosphamid... Etoposide Doxorubicin Vincristine Prednisone Methotrexate Cyclosporine Apheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma | NCT00147875 | Hodgkin's Disea... | Prednisone Vinblastine Doxorubicin (Ad... Gemcitabine | 60 Years - 75 Years | University of Cologne | |
| Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease | NCT00398177 | Lymphoma, Non-H... Hodgkin's Disea... | 18 Years - | Stanford University | ||
| A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor | NCT01696461 | Related Donors ... Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Non-Hodgkin's L... Hodgkin's Disea... Chronic Lymphoc... | Plerixafor | 18 Years - 65 Years | Center for International Blood and Marrow Transplant Research | |
| Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) | NCT01657331 | Hodgkin Lymphom... Anaplastic Larg... | Brentuximab Ved... Bendamustine Neulasta | 18 Years - | Columbia University | |
| Spectroscopy With Surface Coils and Decoupling | NCT00581815 | Adrenal Cortica... Brain Cancer Breast Cancer CNS Cancer Colon Cancer HEENT Cancer Hodgkin's Disea... Kaposi's Sarcom... Liver Cancer Lung Cancer Non-Hodgkin's L... Ovarian Cancer Pancreatic Canc... Prostate Cancer Rectal Cancer Renal Cancer Sarcoma Squamous Cell C... Thyroid Cancer | Proton-decouple... 1H Spectroscopy... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant | NCT00597714 | Hodgkin's Disea... Non Hodgkin's L... Myeloma Leukemia Myelodysplasia | Non-myeloablati... | 18 Years - | Duke University | |
| Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus | NCT00133367 | Multiple Myelom... Non-Hodgkin's L... Hodgkin's Disea... Myelogenous Leu... Lymphoblastic L... | Tacrolimus Sirolimus G-CSF Antithymocyte g... Thymoglobulin Fludarabine Melphalan | 18 Years - 65 Years | Massachusetts General Hospital | |
| CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation | NCT00038818 | Chronic Myeloge... Multiple Myelom... Non Hodgkin's L... Hodgkin's Disea... Chronic Lymphoc... | CD8 Depleted Do... | - | M.D. Anderson Cancer Center | |
| Rituximab and ABVD for Hodgkin's Patients | NCT00504504 | Lymphoma | Rituximab Adriamycin Bleomycin Vinblastine Dacarbazine (DT... | 16 Years - | M.D. Anderson Cancer Center | |
| Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant | NCT01904175 | Hodgkin's Disea... Non Hodgkin's L... Myeloma Leukemia Myelodysplasia | 18 Years - | Duke University | ||
| Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers | NCT00608452 | Lung Cancer Ovarian Cancer Breast Cancer Hodgkin's Disea... Neuroblastoma | Symptom Assessm... | - | Memorial Sloan Kettering Cancer Center | |
| Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies | NCT01221857 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Non-Hodgkin's L... Hodgkin's Disea... | NiCord® | 8 Years - 65 Years | Gamida Cell ltd | |
| Kinetic of Cytokines Decrease and Hodgkin Lymphoma Prognostic | NCT01833884 | Hodgkin's Disea... | Collection of b... | 18 Years - | Centre Henri Becquerel | |
| A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas | NCT00001430 | Hodgkin's Disea... Non Hodgkin's L... | PBSC IL-2 EPOCH II | - | National Institutes of Health Clinical Center (CC) | |
| Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies | NCT00691210 | Hodgkin's Disea... Non-Hodgkin's L... | Vorinostat Niacinamide Etoposide | 18 Years - | Columbia University | |
| Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy | NCT00469729 | Hematologic Mal... Acute Myeloid L... Lymphoid Leukem... Chronic Myeloid... Hodgkin's Disea... Non-Hodgkin's L... Myelodysplastic... | StemEx® | 12 Years - 55 Years | Gamida Cell -Teva Joint Venture Ltd. | |
| Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants | NCT00606437 | Lymphoma Myeloma Leukemia Myelodysplasia Solid Tumors Hodgkin's Disea... Myelofibrosis | Total Body Irra... | 14 Years - 65 Years | Duke University | |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | NCT00990587 | Hematologic Mal... Acute Lymphocyt... Chronic Lymphoc... Myelodysplasia Acute Myeloid L... Chronic Myeloge... Hodgkin's Disea... | Ciclopirox Olam... | 18 Years - | University Health Network, Toronto | |
| Rituximab and ABVD for Hodgkin's Patients | NCT00504504 | Lymphoma | Rituximab Adriamycin Bleomycin Vinblastine Dacarbazine (DT... | 16 Years - | M.D. Anderson Cancer Center | |
| Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | NCT00001830 | Chronic Lymphoc... Graft vs Host D... Hodgkin's Disea... Multiple Myelom... Non Hodgkin's L... | Th2 cells in al... Th2 Cells | 12 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | NCT00975975 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Chronic Lymphoc... Myelodysplasia Non-Hodgkin's L... Hodgkin's Disea... Multiple Myelom... Myelofibrosis Anemia, Aplasti... Hemoglobinuria,... | Basiliximab | 18 Years - | Indiana University | |
| Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children | NCT00552825 | Acute Lymphobla... Acute Myeloblas... Solid Tumors, Hodgkin's Disea... Non-Malignant | 3 Years - 7 Years | Sheba Medical Center | ||
| MSC and HSC Coinfusion in Mismatched Minitransplants | NCT01045382 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Myelo... Myeloproliferat... Myelodysplastic... Multiple Myelom... Leukemia, Lymph... Hodgkin's Disea... Lymphoma, Non-H... | Mesenchymal ste... Isotonic soluti... | - 75 Years | University of Liege | |
| Reproducibility of an Immobilization Device (BodyFIX) - Hodgkins/Lymphoma | NCT00232440 | Hodgkin's Disea... Lymphoma, Non-H... | BodyFIX | 18 Years - | University Health Network, Toronto | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | NCT01321346 | Lymphoblastic L... Myelogenous Leu... Hodgkin's Disea... Non-Hodgkin's L... | Panobinostat Cytarabine Panobinostat | 8 Years - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies | NCT00256191 | Neoplasms Hodgkin's Disea... Non-Hodgkin's L... | TPI 287 Injecti... | 18 Years - 85 Years | Cortice Biosciences, Inc. | |
| Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies | NCT00691210 | Hodgkin's Disea... Non-Hodgkin's L... | Vorinostat Niacinamide Etoposide | 18 Years - | Columbia University | |
| Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies | NCT01471067 | Blood And Marro... Leukemia Lymphoma Transplantation... Transplantation... | Melphalan Fludarabine Mycophenolate m... Tacrolimus Cord Blood Infu... Rituximab ATG Busulfan Clofarabine Total Body Irra... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors | NCT00165308 | Hodgkin's Disea... Breast Cancer | Tamoxifen | 18 Years - 35 Years | Dana-Farber Cancer Institute | |
| Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy | NCT00165438 | Hodgkin's Disea... | Pulmonary Funct... CAT Scan | 18 Years - | Dana-Farber Cancer Institute | |
| High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease | NCT01200329 | Lymphoma | Gemcitabine Busulfan Melphalan Stem Cell Trans... Palifermin | 12 Years - 70 Years | M.D. Anderson Cancer Center | |
| Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination | NCT02007811 | Acute Myeloid L... Acute Lymphobla... Chronic Myeloid... Non Hodgkin's L... Hodgkin's Disea... Myelodysplastic... Multiple Myelom... Aplastic Anemia | allogeneic dono... | 18 Years - 75 Years | University of Erlangen-Nürnberg Medical School | |
| Allogeneic Blood Stem Cell Transplantation | NCT00423709 | Hodgkin's Disea... | Allogeneic Bloo... Fludarabine Melphalan | - 65 Years | M.D. Anderson Cancer Center | |
| Pegfilgrastim PBPC Mobilization Study | NCT00066092 | Lymphoma Hodgkin's Lymph... Non-Hodgkin's L... Hematology Oncology | pegfilgrastim 1... filgrastim pegfilgrastim 6... | 18 Years - | Amgen | |
| Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease | NCT01174940 | Stem Cell Leuke... Graft Versus Ho... | extracorporeal ... | 18 Years - | University of Kansas Medical Center | |
| A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation | NCT00275262 | Hodgkin Disease Lymphoma, Non-H... Multiple Myelom... Mantle Cell Lym... | Leuprolide acet... Matched placebo | 18 Years - 65 Years | Abbott | |
| Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit | NCT01527838 | Non-Hodgkin's L... Hodgkin's Disea... Chronic Lymphoc... Acute Myelogeno... Acute Lymphobla... | Single FT1050 t... | 18 Years - 65 Years | Fate Therapeutics | |
| Rituximab and ABVD for Hodgkin's Patients | NCT00504504 | Lymphoma | Rituximab Adriamycin Bleomycin Vinblastine Dacarbazine (DT... | 16 Years - | M.D. Anderson Cancer Center | |
| Kinetic of Cytokines Decrease and Hodgkin Lymphoma Prognostic | NCT01833884 | Hodgkin's Disea... | Collection of b... | 18 Years - | Centre Henri Becquerel | |
| Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation | NCT01283776 | Multiple Myelom... Non-Hodgkin-Lym... Hodgkin's Disea... | Cyclophosphamid... | 18 Years - | University of Cologne | |
| Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease | NCT01702961 | Lymphoma Hodgkin's Disea... | Melphalan Ara-C VP-16 BCNU Rituxan Stem Cells | - | Baylor College of Medicine | |
| Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor | NCT01350245 | Acute Myeloid L... Myelodysplastic... Biphenotypic Le... Acute Lymphocyt... Chronic Myeloid... Chronic Lymphoc... Plasma Cell Neo... Lymphoma Hodgkin's Disea... Aplastic Anemia | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Mycophenolate M... Tacrolimus Hematopoietic s... | 18 Years - | Thomas Jefferson University | |
| Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function | NCT00652626 | MDS AML Solid Tumors Multiple Myelom... Non-Hodgkin's L... Hodgkin's Disea... | azacitidine | 18 Years - | Celgene | |
| AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease | NCT00396201 | Hodgkin's Disea... | G-CSF Plus Pler... | 18 Years - 70 Years | Sanofi | |
| A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease | NCT00284804 | Hodgkin's Disea... | MDX-060 | 18 Years - | Bristol-Myers Squibb | |
| Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II) | NCT00587873 | Hodgkin's Disea... | Methotrexate Leucovorin calc... 6-Thioguanine | - | Memorial Sloan Kettering Cancer Center | |
| Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT | NCT00506922 | Leukemia Lymphoma | Pentostatin Tacrolimus Methotrexate | - | M.D. Anderson Cancer Center | |
| Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy | NCT00469729 | Hematologic Mal... Acute Myeloid L... Lymphoid Leukem... Chronic Myeloid... Hodgkin's Disea... Non-Hodgkin's L... Myelodysplastic... | StemEx® | 12 Years - 55 Years | Gamida Cell -Teva Joint Venture Ltd. | |
| Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT | NCT00648037 | Hodgkin's Disea... Leukemia Myelodysplastic... Non-Hodgkin's L... | Rituximab | - | Memorial Sloan Kettering Cancer Center | |
| P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies | NCT01854567 | Acute Myelogeno... Acute Lymphobla... Non-Hodgkin's L... Hodgkin's Disea... | Infusion of one... Infusion of two... | - 65 Years | Mesoblast, Ltd. | |
| Allogeneic Transplantation From Related Haploidentical Donors | NCT00185692 | Blood Cancer Leukemia Graft Versus Ho... Malignancy CLL NHL Hodgkin's Disea... MDS | non-myeloablati... Anti-Thymocyte ... Cyclosporine Mycophenolate M... G-CSF Solumedrol Acetaminophen Diphenydramine Hydrocortisone | 12 Months - | Stanford University | |
| Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II) | NCT00587873 | Hodgkin's Disea... | Methotrexate Leucovorin calc... 6-Thioguanine | - | Memorial Sloan Kettering Cancer Center | |
| Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease | NCT01174940 | Stem Cell Leuke... Graft Versus Ho... | extracorporeal ... | 18 Years - | University of Kansas Medical Center | |
| A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy | NCT00261677 | Anemia Hodgkin Disease Leukemia Lymphoma, Non-h... | epoetin alfa | 5 Years - 18 Years | Ortho Biotech Products, L.P. | |
| Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies | NCT00718757 | Non-Hodgkins Ly... Hodgkin's Disea... Acute Lymphobla... | Dexamethasone Irinotecan Vincristine | - 21 Years | St. Jude Children's Research Hospital | |
| Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function | NCT00652626 | MDS AML Solid Tumors Multiple Myelom... Non-Hodgkin's L... Hodgkin's Disea... | azacitidine | 18 Years - | Celgene | |
| Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL) | NCT01300156 | Hodgkin's Lymph... | Oxaliplatin-bas... | 18 Years - 75 Years | National Cancer Center, Korea | |
| Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant | NCT01904175 | Hodgkin's Disea... Non Hodgkin's L... Myeloma Leukemia Myelodysplasia | 18 Years - | Duke University | ||
| Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL | NCT00452374 | Leukemia | Cytarabine Fludarabine Oxaliplatin Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma | NCT00163748 | Non-Hodgkin's L... Hodgkin's Disea... | gemcitabine, vi... | 18 Years - 70 Years | Bayside Health | |
| A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease | NCT00284804 | Hodgkin's Disea... | MDX-060 | 18 Years - | Bristol-Myers Squibb |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
